Litcius/Paper detail

Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment

Paolo Tarantino, Sara M. Tolaney, G. Curigliano

2023Annals of Oncology13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTrastuzumabMetastatic breast cancerOncologyBreast cancerInternal medicineCancerHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment | Litcius